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OBJECTIVE — The metabolic syndrome (MetS) and coronary artery disease (CAD) fre-
quently coincide; their individual contribution to inﬂammation is unknown.
RESEARCH DESIGN AND METHODS — We enrolled 1,010 patients undergoing
coronary angiography. Coronary stenoses 50% were considered signiﬁcant. The MetS was
deﬁned according to American Heart Association–revised National Cholesterol Education Pro-
gram Adult Treatment Panel III criteria.
RESULTS — C-reactive protein (CRP) did not differ between patients with signiﬁcant CAD
and subjects without signiﬁcant CAD (P  0.706) but was signiﬁcantly higher in MetS patients
than in those without MetS (P  0.001). The MetS criteria low HDL cholesterol (P  0.001),
largewaist(P0.001),highglucose(P0.001),andhighbloodpressure(P0.016),butnot
high triglycerides (P  0.352), proved associated with CRP. When all MetS traits were consid-
ered simultaneously, only low HDL cholesterol proved independently associated with CRP (F 
44.19; P  0.001).
CONCLUSIONS — CRP is strongly associated with the MetS but not with coronary athero-
sclerosis. The association of the MetS with subclinical inﬂammation is driven by the low HDL
cholesterol feature.
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A
lthough serum C-reactive protein
(CRP) is an important predictor of
cardiovascular events (1), its cross-
sectional association with the presence
and extent of coronary atherosclerosis is
unclear (2,3). It is therefore ambiguous
whether subclinical inﬂammation in met-
abolic syndrome (MetS) patients is pri-
marily due to the increased prevalence of
(silent) coronary artery disease (CAD) in
these patients or, conversely, whether el-
evated levels of inﬂammation in CAD pa-
tients are primarily due to a correlation
with the MetS. Furthermore, it remains
unclear which classical MetS traits are
most strongly associated with CRP.
RESEARCH DESIGN AND
METHODS— We enrolled 1,047
consecutive Caucasian patients referred
to coronary angiography for the evalua-
tion of stable CAD solely on a clinical in-
dication. Six patients with type 1 diabetes
and31patientswithacuteinfectionswere
excluded.
Coronary angiography was per-
formed as described previously (4); coro-
nary stenoses 50% were considered
signiﬁcant(5,6).TheMetSwasdiagnosed
according to American Heart Associa-
tion–revised National Cholesterol Educa-
tion Program Adult Treatment Panel III
criteria (7). The ethics committee of the
University of Innsbruck approved the
study; all participants gave written in-
formed consent.
Analytical procedures and statistical
analyses
Analytical procedures were performed on
a Cobas Integra 800 (Roche, Basel, Swit-
zerland), as described previously (4,8).
Sample-size calculations showed that as-
suming an SD of 1.5 times the population
mean, 393 patients would be needed per
study group to detect a between-group
difference of CRP of 20% with a power of
80% at an  fault of 0.05. P values 0.05
were considered signiﬁcant. The Hoch-
berg correction for multiple testing was
applied where appropriate. Statistical
analyses were performed with the soft-
ware package SPSS 11.0 for Windows.
RESULTS
Association between the MetS and
angiographically determined
coronary atherosclerosis
Signiﬁcant CAD at angiography was
present in 564 patients (55.8%); its prev-
alence was higher in patients with MetS
than in subjects without MetS (59.5 vs.
52.8%; P  0.034); adjustment for age,
sex,LDLcholesterol,smoking,cardiovas-
cular medications (statins, aspirin, ACE
inhibitors/angiotensin receptor blocking
agents and -blocking agents), and CRP
conﬁrmed this result, with an odds ratio
(OR) of 1.49 (95% CI 1.12–1.98; P 
0.007) for MetS patients.
The low HDL cholesterol (OR 1.57
[95% CI 1.11–2.22]; P  0.011) and the
high-glucose traits (1.33 [1.02–1.73];
P0.038)provedsigniﬁcantlyandinde-
pendently of the above covariates associ-
ated with signiﬁcant CAD, whereas high
triglycerides(P0.082),largewaist(P
0.826), and high blood pressure criteria
(P  0.145) were not independently as-
sociated with signiﬁcant CAD.
CRP, MetS, and CAD
CRP was signiﬁcantly higher in patients
with MetS than in subjects without MetS
(0.46  0.62 vs. 0.35  0.49 mg/dl; P 
0.001).Incontrast,CRPdidnotdiffersig-
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cantCADandsubjectswithoutsigniﬁcant
CAD(0.400.59vs.0.390.52mg/dl;
P  0.706). CRP also was similar in sub-
jectswithanyatheroscleroticlesionatan-
giography compared with subjects with
completely normal coronary arteries
(0.41  0.57 vs. 0.36  0.50 mg/dl; P 
0.325). Furthermore, CRP was not asso-
ciated with signiﬁcant CAD in a multivar-
iate model adjusting for age, sex, LDL
cholesterol, smoking, cardiovascular
medications, and presence of MetS (stan-
dardized adjusted OR 0.97 [95% CI
0.76–1.25]; P  0.822).
Considering both MetS and signiﬁ-
cantCAD,CRPwassigniﬁcantlyhigherin
patients with MetS, both among those
without signiﬁcant CAD (0.45  0.50 vs.
0.36  0.53 mg/dl; P  0.001) and
among those with signiﬁcant CAD
(0.470.69vs.0.340.45;P0.001).
In contrast, CRP did not differ between
patients with signiﬁcant CAD and those
without signiﬁcant CAD among subjects
without MetS (P  0.869) or among sub-
jects with MetS (P  0.411).
ANCOVA,adjustingforage,sex,LDL
cholesterol, smoking, and cardiovascular
medications, conﬁrmed that MetS (F 
11.74; P  0.001) but not signiﬁcant
CAD (F  0.01; P  0.983) was signiﬁ-
cantly associated with CRP.
Associations of individual MetS
components with CRP
Univariately,serumCRPwassigniﬁcantly
higher in patients who fulﬁlled the large
waist (P  0.001), the low HDL choles-
terol(P0.001),thehighbloodpressure
(P  0.016), and the high glucose (P 
0.001) criteria but not in patients who
fulﬁlled the high triglyceride criterion
(P  0.352) compared with patients who
did not fulﬁll the respective MetS criteria.
When all MetS traits were entered simul-
taneously into one ANCOVA model, only
low HDL cholesterol proved associated
with CRP (F  44.19; P  0.001) inde-
pendently of age, sex, LDL cholesterol,
smoking, major cardiovascular medica-
tions, and of all other MetS criteria.
CRP increased signiﬁcantly (Ptrend
0.001) with an increasing number of
MetS traits (Fig. 1A) after adjustment for
age, sex, smoking, LDL cholesterol, and
major cardiovascular medications. Fur-
ther adjustment for the high waist (F 
11.66; P  0.001), the high glucose (F 
14.18; P  0.001), the high blood pres-
sure(F17.94;P0.001),andthehigh
triglyceride (F  32.81; P  0.001) traits
rendered this relationship virtually un-
changed. In contrast, the positive associ-
ation between the number of metabolic
traits and CRP was no longer signiﬁcant
(Fig.1B)afteradjustmentforthelowHDL
cholesterol criterion (F  0.87; P 
0.352).
CONCLUSIONS— From our data,
we conclude that among angiographied
coronary patients CRP is strongly associ-
ated with the MetS but not with angio-
graphically characterized coronary
atherosclerosis. Speciﬁcally, the overall
associationoftheMetSwithCRPisdriven
by the low HDL cholesterol feature.
Data from the literature on the asso-
ciation of CRP with cross-sectionally de-
termined CAD are controversial. Most
studies have not found such an associa-
tion (2,9–12). This observation likely re-
ﬂects the fact that inﬂammation is not
associated with plaque burden itself but
rather with plaque vulnerability and rup-
ture. Thus, our data do not contradict the
numerous reports on an association be-
tween CRP and clinical atherothrombotic
events.
Further, our data show that the low
HDL cholesterol MetS feature drives the
overall association between the MetS and
CRP; CRP was no longer associated with
the number of MetS traits when adjusted
for HDL cholesterol. These data ﬁt into
the notion that HDL particles, besides
their crucial role in reverse cholesterol
transport, also protect the artery wall
through anti-inﬂammatory mechanisms
(13). Thus, CRP is strongly associated
with the MetS but not with angiographi-
cally diagnosed coronary atherosclerosis.
The overall association of the MetS with
CRP is predominantly driven by the low
HDL cholesterol feature, a paramount
predictor of vascular events.
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